Brainstorm Cell Therapeutics Inc. (BCLI) financial statements (2020 and earlier)

Company profile

Business Address 1325 AVENUE OF AMERICAS
NEW YORK, NY 10019
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17810169
Cash and cash equivalents112104
Short-term investments0659164
Receivables221011
Prepaid expense011  0
Other undisclosed current assets00000 
Total current assets:31010101710
Noncurrent Assets
Property, plant and equipment     0
Long-term investments and receivables     0
Long-term investments     0
Prepaid expense     0
Other noncurrent assets31200 
Other undisclosed noncurrent assets     (0)
Total noncurrent assets:312000
TOTAL ASSETS:71111111710
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1662033
Accounts payable1551012
Accrued liabilities111021
Debt1     
Other undisclosed current liabilities113000
Total current liabilities:1866133
Noncurrent Liabilities
Long-term debt and lease obligation1     
Operating lease, liability1
Other undisclosed noncurrent liabilities     0
Total noncurrent liabilities:1    0
Total liabilities:1966133
Stockholders' equity
Stockholders' equity attributable to parent, including:(12)5610147
Common stock000000
Additional paid in capital1059586858468
Accumulated deficit(117)(94)(80)(75)(70)(62)
Warrants and rights outstanding     0
Other undisclosed stockholders' equity attributable to parent 4   (0)
Total stockholders' equity:(12)5610147
TOTAL LIABILITIES AND EQUITY:71111111710

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(23)(14)(5)(5)(9)(7)
Other undisclosed operating loss     (2)
Operating loss:(23)(14)(5)(5)(9)(9)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(0)0000 
Net loss available to common stockholders, diluted:(23)(14)(5)(5)(8)(9)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(23)(14)(5)(5)(8)(9)
Comprehensive loss, net of tax, attributable to parent:(23)(14)(5)(5)(8)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: